Publications

2021

Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021;131(10).
Malapelle U, Pisapia P, Addeo A, Arrieta O, Bellosillo B, Cardona AF, et al. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Rev Mol Diagn. 2021;21(11):1165-1178.
Patel SS. Pediatric Myelodysplastic Syndromes. Clin Lab Med. 2021;41(3):517-528.
Choi JJ, Westblade LF, Gottesdiener LS, Liang K, Li HA, Wehmeyer GT, et al. Impact of a Multiplex Polymerase Chain Reaction Panel on Duration of Empiric Antibiotic Therapy in Suspected Bacterial Meningitis. Open Forum Infect Dis. 2021;8(10):ofab467.
Hu Q, Poulose N, Girmay S, Helevä A, Doultsinos D, Gondane A, et al. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA Biol. 2021:1-8.
Jalloul N, Gomy I, Stokes S, Gusev A, Johnson BE, Lindeman NI, et al. Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing. JCO Precis Oncol. 2021;5.
Yang HS, LaFrance DR, Hao Y. Elemental Testing Using Inductively Coupled Plasma Mass Spectrometry in Clinical Laboratories. Am J Clin Pathol. 2021;156(2):167-175.
Lopez A, Patel S, Geyer JT, Racchumi J, Chadburn A, Simonson P, et al. Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Front Oncol. 2021;11:701318.
Slaughter MJ, Shanle EK, Khan A, Chua KF, Hong T, Boxer LD, et al. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell Rep. 2021;34(3):108638.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700